MedTrace Logo

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

NCT00812240 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 335

Last updated 2023-02-01

No results posted yet for this study

Summary

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Conditions

Interventions

DRUG

Masitinib

DRUG

Imatinib

imatinib 400 mg or 600 mg per day, per os

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Antoine Adenis, MD · Centre Oscar Lambret, Lille, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2018-07-31
Completion
2018-07-31
FDA Drug
Yes

Countries

  • United States
  • France
  • Lebanon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812240 on ClinicalTrials.gov